K L Flanagan - JoVE Visualize

Showing results (11-20 of 24) with videos related to

Pageof 3

Sort By:

Immunity|July 14, 1999

Interleukin 10-mediated immunosuppression by a variant CD4 T cell epitope of Plasmodium falciparumM Plebanski, K L Flanagan, E A Lee, et al.

The American Journal of Tropical Medicine and Hygiene|July 10, 2001

Identification of frequently recognized dimorphic T-cell epitopes in plasmodium falciparum merozoite surface protein-1 in West and East Africans: lack of correlation of immune recognition and allelic prevalenceE A Lee, K L Flanagan, K Odhiambo, et al.

Infection and Immunity|February 21, 2002

Naturally exposed populations differ in their T1 and T2 responses to the circumsporozoite protein of Plasmodium falciparumW H H Reece, M Plebanski, P Akinwunmi, et al.

Journal of Immunology (Baltimore, Md. : 1950)|October 10, 2001

Unique T cell effector functions elicited by Plasmodium falciparum epitopes in malaria-exposed Africans tested by three T cell assaysK L Flanagan, E A Lee, M B Gravenor, et al.

Journal of Medicinal Chemistry|August 20, 1993

Triazolinones as nonpeptide angiotensin II antagonists. 1. Synthesis and evaluation of potent 2,4,5-trisubstituted triazolinonesL L Chang, W T Ashton, K L Flanagan, et al.

Journal of Medicinal Chemistry|September 15, 1995

Potent and orally active angiotensin II receptor antagonists with equal affinity for human AT1 and AT2 subtypesL L Chang, W T Ashton, K L Flanagan, et al.

Journal of Medicinal Chemistry|December 23, 1994

Triazolinone biphenylsulfonamides as angiotensin II receptor antagonists with high affinity for both the AT1 and AT2 subtypesL L Chang, W T Ashton, K L Flanagan, et al.

Journal of Medicinal Chemistry|August 19, 1994

Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinityW T Ashton, L L Chang, K L Flanagan, et al.

Allergy|December 29, 2015

Timing of routine infant vaccinations and risk of food allergy and eczema at one year of ageN Kiraly, J J Koplin, N W Crawford, et al.

Clinical and Experimental Immunology|January 24, 2004

Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The GambiaM Pinder, W H H Reece, M Plebanski, et al.

Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:

Pageof 3

Immunity|July 14, 1999

Interleukin 10-mediated immunosuppression by a variant CD4 T cell epitope of Plasmodium falciparumM Plebanski, K L Flanagan, E A Lee, et al.

The American Journal of Tropical Medicine and Hygiene|July 10, 2001

Identification of frequently recognized dimorphic T-cell epitopes in plasmodium falciparum merozoite surface protein-1 in West and East Africans: lack of correlation of immune recognition and allelic prevalenceE A Lee, K L Flanagan, K Odhiambo, et al.

Infection and Immunity|February 21, 2002

Naturally exposed populations differ in their T1 and T2 responses to the circumsporozoite protein of Plasmodium falciparumW H H Reece, M Plebanski, P Akinwunmi, et al.

Journal of Immunology (Baltimore, Md. : 1950)|October 10, 2001

Unique T cell effector functions elicited by Plasmodium falciparum epitopes in malaria-exposed Africans tested by three T cell assaysK L Flanagan, E A Lee, M B Gravenor, et al.

Journal of Medicinal Chemistry|August 20, 1993

Triazolinones as nonpeptide angiotensin II antagonists. 1. Synthesis and evaluation of potent 2,4,5-trisubstituted triazolinonesL L Chang, W T Ashton, K L Flanagan, et al.

Journal of Medicinal Chemistry|September 15, 1995

Potent and orally active angiotensin II receptor antagonists with equal affinity for human AT1 and AT2 subtypesL L Chang, W T Ashton, K L Flanagan, et al.

Journal of Medicinal Chemistry|December 23, 1994

Triazolinone biphenylsulfonamides as angiotensin II receptor antagonists with high affinity for both the AT1 and AT2 subtypesL L Chang, W T Ashton, K L Flanagan, et al.

Journal of Medicinal Chemistry|August 19, 1994

Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinityW T Ashton, L L Chang, K L Flanagan, et al.

Allergy|December 29, 2015

Timing of routine infant vaccinations and risk of food allergy and eczema at one year of ageN Kiraly, J J Koplin, N W Crawford, et al.

Clinical and Experimental Immunology|January 24, 2004

Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The GambiaM Pinder, W H H Reece, M Plebanski, et al.

Pageof 3